ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2567

Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates

Tatiana Pedrosa 1, Sandra G. Pasoto 1, Emily Yuki2, Nadia Aikawa 1, Eduardo Borba 1, Julio Ferreira Filho 1, Pedro Carricondo 3, Caio Zanetti 1, Paola Conde 1, Nicole Fontoura 1, Paschoalina Romano 4, Valdemir Carvalho 5, Clovis Silva 6 and Eloisa Bonfa 7, 1Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 2Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., São Paulo, Brazil, 3Ophtalmology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 4Division of Central Laboratory, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 5Fleury Group, Sao Paulo, Brazil, Sao Paulo, Brazil, 6Pediatric Rheumatology Unit, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 7Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: flare, Hydroxychloroquine, lipoprotein and liquid chromatography-mass spectrometry, Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Hydroxychloroquine (HCQ) is the most well established therapy for SLE, as it provides several beneficial properties, such as favorable effects on lipid profile, reduced cardiovascular (CV) risk and reduction in flares. However, one of the main concerns about HCQ use is retinopathy. In this regard, the American Academy of Ophthalmology (AAO) recently recommended the maximum daily dose of 5.0 mg/kg of real weight but this recommendation is only focused on retinal safety and there are no data evaluating if reduced doses would sustain the beneficial effects of this drug with regard to lipid profile and flare rates. Therefore, the aim of this study was to prospectively assess lipid profile and flare rate in high-risk retinopathy stable LN patients using low dose HCQ AAO recommendation.

Methods: Eighty-two stable LN patients (6-months before entry), ≥5 years of HCQ were evaluated at entry and after 6-months (6M). None of them had retinopathy (spectral-domain optical coherence tomography). HCQ blood levels were determined by liquid chromatography-mass spectrometry. Fasting lipoproteins/blood glucose levels were determined et entry and 6M. Flare was defined as increase in SLEDAI-2K≥3 and/or change in therapy. We also evaluated retrospectively lipid profile, high CV risk and flare rates before HCQ dose reduction according to AAO and compared to the same patients at the end of prospective analysis.

Results: Total/LDL/HDL cholesterol and triglyceride levels remained stable throughout the study (p >0.05) and no significant differences were observed in frequencies of high CV risk levels (p >0.05). Nine of 82 LN patients (10.97%) had flare during the 6-months follow-up. HCQ blood levels were significantly lower in patients with compared to those without flare [220.4(32.1-1471.7) vs. 986.6(26.1-4265.0)ng/mL, p=0.015]. Comparisons of other baseline characteristics demonstrated similar demographic data, disease parameters and concomitant treatment of LN patients with and without flare. An HCQ blood level cut-off of 607ng/ml was a predictor of 6-months flare [OR=5.67, 95%CI 1.34-24.03; sensitivity 78%, specificity 71%, p=0.002). Of note, retrospective analysis revealed comparable lipoprotein and glycemia levels as well as, frequencies of high CV risk and flare rates (9% vs. 10%, p=0.751) before and after AAO dose reduction (Table 1). HCQ blood levels were classified in low (< 607 ng/mL) or adequate (≥607 ng/mL) according to the cut-off level. At 6M evaluation, blood HCQ levels remained within the same range in 67 patients (82%), whereas it turned from low to adequate in six and from adequate to low in nine patients (McNemar’s test, p= 0.606) (Figure 1).

Conclusion: We provide novel evidence that AAO HCQ low dose recommendation in stable LN patients with high-risk retinopathy is not associated with a deleterious effect on lipid profile or increased flare rates. This finding supports the notion that this new regimen retains the beneficial effect of HCQ with the advantage of a lower long-term cumulative dose and toxicity.


Table 1

Table 1 – Lipoprotein and glycemia levels, and frequencies of lipoprotein high cardiovascular risk in 53 patients with lupus nephritis before -retrospective evaluation- versus after hydroxychloroquine American Academy of Ophthalmology -AAO- dose reduction -end of prospective analysis-


Figure 1

Figure 1 – Prospective evaluation of hydroxychloroquine blood levels at baseline and after 6 months in lupus nephritis patients. The dotted line indicates blood HCQ cut-off level for disease flare.


Disclosure: T. Pedrosa, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2017/14352-7), 2; S. Pasoto, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2015/03756-4), 2; E. Yuki, None; N. Aikawa, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2015/03756-4), 2; E. Borba, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2015/03756-4), 2, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq #306879/2018-2), 2; J. Ferreira Filho, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2017/11516-9), 2; P. Carricondo, None; C. Zanetti, None; P. Conde, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2017/11854-1), 2; N. Fontoura, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2017/11644-7), 2; P. Romano, None; V. Carvalho, None; C. Silva, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2015/03756-4), 2, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq #303422/2015-7), 2; E. Bonfa, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq #305068/2014-8), 2, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2015/03756-4 and #2010/10749-0), 2.

To cite this abstract in AMA style:

Pedrosa T, Pasoto S, Yuki E, Aikawa N, Borba E, Ferreira Filho J, Carricondo P, Zanetti C, Conde P, Fontoura N, Romano P, Carvalho V, Silva C, Bonfa E. Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/prospective-evaluation-of-american-academy-of-ophthalmology-low-dose-hydroxychloroquine-recommendation-in-stable-lupus-nephritis-with-high-risk-retinopathy-lipid-profile-and-flare-rates/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prospective-evaluation-of-american-academy-of-ophthalmology-low-dose-hydroxychloroquine-recommendation-in-stable-lupus-nephritis-with-high-risk-retinopathy-lipid-profile-and-flare-rates/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology